Pancytopenia in a patient treated with fusidic acid and niraparib: a case report.


Journal

European journal of hospital pharmacy : science and practice
ISSN: 2047-9956
Titre abrégé: Eur J Hosp Pharm
Pays: England
ID NLM: 101578294

Informations de publication

Date de publication:
09 2023
Historique:
received: 29 04 2021
accepted: 08 02 2022
medline: 25 8 2023
pubmed: 3 3 2022
entrez: 2 3 2022
Statut: ppublish

Résumé

Fusidic acid is an antibiotic used in the treatment of staphylococcal infections. Niraparib is an anticancer drug indicated for the treatment of advanced ovarian cancer. The interaction between these two drugs has not been studied and is not referenced in drug databases. We present the case of a patient with pancytopenia who had been treated with fusidic acid and niraparib. No other treatment was taken by this patient. According to the literature, both substances can cause haematological toxicity. It seems unlikely that this is due to niraparib alone because it had been well tolerated by the patient for over a year before the pancytopenia was diagnosed. It was also perfectly well tolerated when it was reintroduced. We cannot determine whether this pancytopenia is due to fusidic acid alone or to a drug interaction between the two treatments. We therefore recommend caution in patients treated with this combination.

Identifiants

pubmed: 35232830
pii: ejhpharm-2021-002819
doi: 10.1136/ejhpharm-2021-002819
pmc: PMC10447960
doi:

Substances chimiques

Fusidic Acid 59XE10C19C
niraparib HMC2H89N35
Anti-Bacterial Agents 0
Indazoles 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e24

Informations de copyright

© European Association of Hospital Pharmacists 2023. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Clin Infect Dis. 2011 Jun;52 Suppl 7:S527-37
pubmed: 21546630
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Br J Clin Pharmacol. 2017 May;83(5):1039-1047
pubmed: 27813241
Br J Clin Pharmacol. 2000 Jul;50(1):82-3
pubmed: 10886126
Gynecol Oncol. 2018 Apr;149(1):214-220
pubmed: 29397193

Auteurs

Margaux Damerval (M)

Territoire de Belfort, Hopital Nord Franche-Comte - Site de Belfort, Trévenans, Franche-Comté, France margaux.damerval@orange.fr.

Fernando Bazan (F)

Doubs, Centre Hospitalier Universitaire de Besancon, Besancon, France.

Selim Omrani (S)

Territoire de Belfort, Hopital Nord Franche-Comte - Site de Belfort, Trévenans, Franche-Comté, France.

Marion Hugues (M)

Territoire de Belfort, Hopital Nord Franche-Comte - Site de Belfort, Trévenans, Franche-Comté, France.

Marie-Françoise Roux (MF)

Territoire de Belfort, Hopital Nord Franche-Comte - Site de Belfort, Trévenans, Franche-Comté, France.

Joséphine Mayer (J)

Territoire de Belfort, Hopital Nord Franche-Comte - Site de Belfort, Trévenans, Franche-Comté, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH